BUENOS AIRES (Reuters) - Argentines living with HIV/AIDS and medics say spending cuts under libertarian President Javier ...
Interesting Engineering on MSN57m
From chronic to curable: Twice-yearly shot shows near-total HIV eradicationConducted by Emory University and Grady Health System and funded by Gilead, the trial showed that Lenacapavir offers a ...
Argentinian President Javier Milei has raised concerns for the HIV/AIDS patients and medics with his fiscal deficit ...
Drugmaker Gilead said it will allow cheap, generic versions to be sold in 120 poor countries with high HIV rates, mostly in ...
Lenacapavir, a new twice-yearly injection, offers 96% HIV prevention efficacy, surpassing daily oral PrEP. For oral ...
A twice-yearly shot shows 100% effectiveness against HIV, but concerns arise over accessibility in Latin America and other ...
Another drugmaker, Viiv Healthcare, also left out most of Latin America when it allowed generics of its HIV prevention shot ...
Lenacapavir, an injectable PrEP taken twice a year, demonstrated 96% efficacy in preventing HIV infections in a global Phase ...
Discover the groundbreaking results of Lenacapavir, a twice-yearly injection that reduces HIV infection risk offering an ...
Recent results from a recent clinical trial indicate that a twice-yearly injection of Lenacapavir offers an overall 96% reduced risk of acquiring HIV. This makes Lenacapavir significantly more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback